CFDA Says ‘Bring It On’ As Clinical Data Stress Test Nears
This article was originally published in PharmAsia News
With 12 days to go before a hard deadline for manufacturers to submit clinical data audit results for over 1,000 drugs, China FDA officials have told company representatives that no stone will be left unturned when they go through the submissions.
You may also be interested in...
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.